11/20
06:07 am
mdgl
Rating for MDGL
Medium
Report
Rating for MDGL
11/20
06:07 am
mdgl
Rating for MDGL
Medium
Report
Rating for MDGL
11/5
08:18 am
mdgl
Rating for MDGL
Medium
Report
Rating for MDGL
11/5
07:19 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/4
06:02 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
11/4
04:14 pm
mdgl
Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald
Medium
Report
Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald
11/3
08:03 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating. They now have a $445.00 price target on the stock, up previously from $266.00.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating. They now have a $445.00 price target on the stock, up previously from $266.00.
10/10
01:50 pm
mdgl
Rating for MDGL
Low
Report
Rating for MDGL
10/10
01:50 pm
mdgl
Rating for MDGL
Low
Report
Rating for MDGL
9/12
08:54 am
mdgl
Rating for MDGL
Low
Report
Rating for MDGL